Advertisement
Advertisement
CYTK
Cytokinetics Inc.
73.45
USDSponsored
-2.19
-2.90%
Aug 13, 15:59 UTC -4
Closed
After-Market
73.75
+0.30
+0.41%
CYTK Earnings Reports
Positive Surprise Ratio
CYTK beat 16 of 42 last estimates.
38%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$37.53M
/-$1.52
Implied change from Q2 26 (Revenue/ EPS)
+31.11%
/+1.33%
Implied change from Q3 25 (Revenue/ EPS)
+1838.45%
/-40.16%
Cytokinetics Inc. earnings per share and revenue
On Aug 06, 2026, CYTK reported earnings of -1.50 USD per share (EPS) for Q2 26, beating the estimate of -1.67 USD, resulting in a 10.35% surprise. Revenue reached 28.62 million, compared to an expected 17.73 million, with a 61.45% difference. The market reacted with a -5.67% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -1.52 USD, with revenue projected to reach 37.53 million USD, implying an increase of 1.33% EPS, and increase of 31.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.18
Actual
-$1.44
Surprise
-21.23%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
MiNK Therapeutics, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.61
Actual
-$0.62
Surprise
-1.31%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
FAQ
What were Cytokinetics Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cytokinetics Inc. reported EPS of -$1.50, beating estimates by 10.35%, and revenue of $28.62M, 61.45% above expectations.
How did the market react to Cytokinetics Inc.'s Q2 2026 earnings?
The stock price moved down -5.67%, changed from $81.37 before the earnings release to $76.76 the day after.
When is Cytokinetics Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Cytokinetics Inc.'s next earnings report?
Based on 10
analysts, Cytokinetics Inc. is expected to report EPS of -$1.52 and revenue of $37.53M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement